XML 54 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Product revenues:      
Related party $ 1,845,000 $ 0 $ 0
Third party 5,277,000 8,709,000 7,983,000
Total product revenues 7,122,000 8,709,000 7,983,000
Cost of product revenues 3,421,000 4,000,000 3,837,000
Gross profit 3,701,000 4,709,000 4,146,000
Development revenues:      
Development, related party 638,000 2,882,000 1,992,000
Development 1,179,000 2,529,000 0
Government contracts and other 3,257,000 381,000 21,000
Total development revenues 5,074,000 5,792,000 2,013,000
Operating expenses:      
Research and development 17,065,000 13,628,000 10,904,000
Sales and marketing 9,026,000 9,488,000 13,560,000
General and administrative 16,031,000 15,672,000 14,727,000
Change in fair value of warrants (418,000) (209,000) (4,360,000)
Change in fair value of option liability (2,250,000) 340,000 740,000
Total operating expenses 39,454,000 38,919,000 35,571,000
Operating loss (30,679,000) (28,418,000) (29,412,000)
Other income (expense):      
Loss on asset disposal (257,000) 0 0
Loss on debt extinguishment (708,000) 0 0
Interest income 4,000 4,000 9,000
Interest expense (3,396,000) (3,386,000) (2,784,000)
Other income (expense), net (438,000) (314,000) (55,000)
Gain on Puregraft divestiture 4,453,000 0 0
Gain on previously held equity interest in joint venture 4,892,000 0 0
Equity loss from investment in joint venture (48,000) (165,000) (209,000)
Total other income (expense) 4,502,000 (3,861,000) (3,039,000)
Net loss (26,177,000) (32,279,000) (32,451,000)
Other comprehensive income (loss) - foreign currency translation adjustments 256,000 0 0
Comprehensive loss $ (25,921,000) $ (32,279,000) $ (32,451,000)
Basic and diluted net loss per common share (in dollars per share) $ (0.39) $ (0.55) $ (0.61)
Basic and diluted weighted average common shares (in shares) 67,781,364 58,679,687 53,504,030